A company that provides health economic research, communications, and consulting services to the global pharmaceutical industry has been acquired by a US private equity firm.
Arsenal Capital Partners, which specialises in healthcare and specialty industrials companies, has acquired Sheffield-based BresMed Health.
BresMed supports pharmaceutical companies and medical device manufacturers to identify, evaluate and demonstrate the clinical and economic value of their products to governments and other healthcare payers and providers.
The company opened its global headquarters at Steel City House in Sheffield last year. It also has offices in Manchester, Dublin, the US, India and the Netherlands.
The deal represents the first in a series of investments to form a new value demonstration company in the market access, health economics and outcomes research, patient preference, and real world evidence space.
The new company will support biopharmaceutical clients with the strategy, evidence and communication tools to help maximize the value of their products.
Arsenal's investment in BresMed has been made in partnership with a team of senior executives, led by Jon Williams, former chief executive of Evidera.
Nic Brereton, BresMed chief exeutive and founder, who will continue to lead the company, said: "We are proud of the company that we have created and are poised for an exciting new chapter. After dozens of discussions, Arsenal stood out as the best partner for BresMed.
"Arsenal shares our bold vision for the future, has a deep understanding of the space, and has strong cultural alignment. I am confident that in partnership with our clients we will have a transformational impact on the speed, efficiency and quality of evidence required to support industry decision making."
Gene Gorbach, an investment partner of Arsenal, said: "Arsenal is building businesses to tackle some of healthcare's most pressing challenges. Our investment in BresMed is the foundation to a platform that will help pharmaceutical companies substantiate and convey the value of their products — a critical need in drug development. We are delighted to partner with the talented group at BresMed and our executive team in this important endeavor."
Jon Williams, who will assume leadership of Arsenal's value demonstration company, added: "BresMed is a global leader in health economics and payer value submissions, with a sterling reputation for quality and scientific leadership. We are thrilled the BresMed team is joining us on this journey and sure that together we will break new ground in addressing some of the most important opportunities for the biopharmaceutical industry."
Sourced from Insider Media Limited - Written by Stephen Farrell